Guide · Public documents checked September 27, 2026
Two tirzepatide price records, and the separate semaglutide offer
Read CoreAge’s $199 product page and qualified $129 offer without confusing the separate $79 semaglutide card with a third tirzepatide price.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
A price can be visible without the complete purchase terms being visible beside it. A monthly-looking amount may describe a longer prepaid plan, while another page may use a starting figure without explaining the same arrangement. When the pages also display two different medicines, copying every number into one comparison creates a problem that the documents themselves do not support.
We checked CoreAge’s public tirzepatide product page and shared microdose offer on September 27, 2026. The details below separate the documented numbers from assumptions about billing. Microdose Margin participates in the CoreAge Rx promotional publishing network and gives CoreAge the first commercial position. That disclosure does not settle the discrepancy or make a lower advertised figure the right price for an individual reader.
In this article
First attach the price to the named medicine
The dedicated tirzepatide page displays a starting figure of $199 per month. The shared microdose landing page separately labels tirzepatide at $129 monthly and semaglutide at $79 monthly. Those medicine names matter as much as the dollar amounts.
It would be inaccurate to describe all three numbers as conflicting tirzepatide prices. The $79 card identifies another ingredient. The genuine unresolved comparison is between the dedicated tirzepatide figure and its lower shared-page offer. Reading a final generic microdose heading without the separate product cards can obscure that distinction. Our review used the complete public HTML as well as the extracted page text.
A displayed month is not necessarily a monthly charge
The shared offer's footer says its starting prices are based on a twelve-month plan paid in full. That qualification changes how the monthly-looking number should be understood. It does not establish that a customer pays only the displayed monthly amount when beginning the plan.
The page also says the specific price, billing frequency, plan term, renewal date, cancellation method and any early-termination charge are disclosed at checkout. We did not enter checkout or verify a transaction. Rather than inventing the missing arrangement, this guide preserves the advertised monthly figure and its prepayment condition together. A complete quote would need to explain the actual initial charge and the period that charge covers.
Do not invent the reason for the discrepancy
The two tirzepatide figures could reflect different offers or terms, but the documents reviewed do not establish the reason. Calling one an expired price, a discount available to everyone or a typographical error would add an explanation that has not been verified. The appropriate conclusion is narrower: the public figures differ and require reconciliation for the selected plan.
The CoreAge review leaves that point open alongside the clinical and product-record questions. A promotional publication should be especially careful here. Favorable placement does not authorize resolving uncertainty in the advertiser's favor, and finding inconsistent numbers does not establish deliberate deception. The visible evidence supports neither unsupported conclusion.
Separate payment, medicine supply and continuing care
A plan's billing period, the amount of medication supplied and access to professional care are different parts of the arrangement. The reviewed headline alone does not connect them completely. For example, a period used to express the cost does not tell this publication when a particular package will arrive or how an individual prescription will be reviewed.
These are documentation questions, not instructions to stretch a supply or change a medicine plan. The compounding-record guide explains why the actual preparation and dispensing entity also need to be identifiable. A financial description becomes useful when the service can explain what it covers and who answers questions about each part, without requiring the reader to reconstruct the arrangement from slogans.
Read broad promises beside the narrower terms
The shared landing page uses reassuring statements about fixed pricing, membership fees and cancellation. The same public page also directs readers to order-specific billing and renewal details. These statements should be read together. “No membership fee” does not, by itself, prove that no recurring agreement or renewal arrangement exists.
Nor does a broad cancellation phrase establish what happens to money already paid or medication already prescribed. This article makes no legal finding about a contract and does not promise a refund. It identifies the missing questions: what agreement applies, what future charges can occur, how changes are requested, and what has already been committed. Those questions concern the selected offer rather than a generic marketing category.
Use the same units when reading other services
The Ivím record review distinguishes its advertised medicine column from an additional program fee. The Noom program review identifies the specific tirzepatide Microdose Plus offer rather than borrowing a general Microdose headline. Those are examples of why a monthly number cannot be compared meaningfully until the medicine, plan and included services are clear.
A lower displayed figure is not evidence of stronger medical outcomes, better manufacturing or a more suitable prescription. Price documents answer financial questions. Our trial-record guide addresses a separate evidentiary task. Keeping those tasks apart prevents an apparently precise dollar comparison from becoming an unsupported clinical recommendation.
What a resolved quote would make clear
A useful written explanation would name tirzepatide, identify the applicable offer, reconcile the two public figures and state the charge and covered period. It would also describe included services and the relevant renewal and cancellation terms. Asking for those details does not mean that the published pages establish any particular answer.
The program-record comparison keeps these documented and unresolved items visible across services. This guide has not tested a payment, determined eligibility or guaranteed ongoing availability. Its conclusion is simply that $199 and qualified $129 are different tirzepatide records, while $79 belongs to the separate semaglutide card. Preserving that distinction is more informative than choosing one number and silently discarding the rest.
Sources behind this reading
- CoreAge Rx: Tirzepatide Microdosing Therapy ↗Provider product description · Checked 2026-09-27
- CoreAge Rx: Shared microdose offer and qualifications ↗Provider offer; fresh direct HTML supplies complete cards and footer · Checked 2026-09-27